The FDA has published more than 200 complete response letters, sent as replies for applications submitted from 2020 to 2024.

Cancer patients without health insurance have not derived the same benefits from the introduction of ICIs as patients with private insurance.

The addition of metformin “was generally well tolerated but did not result in the targeted benefit of a 20% reduction in risk of death in an unselected population,” the researchers wrote.

Mass firings and grant terminations have disrupted research and other operations at the National Cancer Institute.

Olaparib demonstrated activity in a phase 2 trial of patients who had advanced biliary tract cancer with homologous recombination repair (HRR) mutations. Results from this trial were presented at the ...

The Trump administration's recent travel and visa restrictions are preventing medical residents from starting their jobs in the US.

Cancer Therapy Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve ...

The denosumab biosimilars Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) are now available in the US.

Chemotherapy can increase mutation burden and change the cell population structure of normal blood, which contributes to long-term adverse effects such as second malignancies and infertility, ...

The NIH is planning to limit how much publishers can charge NIH-supported scientists to make their research findings publicly available.

Adding atezolizumab and bevacizumab to TACE can improve outcomes in previously untreated, unresectable HCC, data suggest.

Under the “One Big Beautiful Bill Act,” 10.9 million Americans would lose health insurance by 2034, according to estimates from the Congressional Budget Office.